PerkinElmer To Acquire Lifescience Firm BioLegend For $5B; Q2 Earnings Beat Estimates


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • PerkinElmer Inc's (NYSE:PKIhas agreed to acquire privately-held BioLegend for $5.25 billion in cash and stock.
  • The BioLegend deal will expand PerkinElmer's existing life science franchise into new segments. The company expects to close the deal by the end of 2021.
  • BioLegend, which has more than 700 employees, estimates to report 2022 revenues of $380 million.
  • The company expects the combination to be accretive to its existing revenue growth and margin profile and provide an estimated $0.30 of adjusted EPS accretion in the first full year and greater than $0.50 in the second year following close.
  • The combined entity will generate immediate revenue synergies, expected to reach $100 million annually by the fifth year following the transaction close.
  • Results: Q2 adjusted EPS reached $2.83, beating the consensus of $2.41 and 80% higher than $1.57 posted a year ago.
  • It clocked Q2 sales of $1.23 billion ahead of the analyst consensus of $1.12 billion and up 51% Y/Y, with organic growth of 41%.
  • Adjusted operating income of $411 million increased 80%, and margin improved around 540 basis points to 33.5%.
  • Diagnostic segment sales increased 70% Y/Y to $716 million, and organic revenue increased 59%.
  • Discovery & Analytical Solutions business generated sales of $513 million, +31% on the reported basis and 22% higher organically.
  • Guidance: For Q3 of 2021, the company forecasts adjusted EPS of $1.62 below the consensus of $1.72.
  • It sees adjusted revenue of approximately $1.00 billion, higher than the consensus of $983.7 million.
  • For the full year 2021, the company raised the adjusted EPS outlook to $9.88 from the prior outlook of $9.40, versus the consensus of $9.32.
  • It expects 2021 adjusted revenue of $4.57 billion, surpassing the estimate of $4.4 billion.
  • Price Action: PKI shares closed at $164.34 on Friday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: EarningsM&ANewsGuidanceHealth CareGeneralBriefs